Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IV vs Oral Psilocybin
NCT05467761Phase 1Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in psychological distress, major depressive disorder (MDD), anxiety disorder and 3 more, sponsored by University of Wisconsin–Madison. Primary endpoints: Maximum Plasma Concentration at Day 22, Area Under the Curve at Day 22 and 2 more. Planned start Jun 2023; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
psychological distressmajor depressive disorder (MDD)anxiety disordertreatment-resistant depression (TRD)nicotine dependence (ND)
Beyond the preview
Go deeper on NCT05467761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467761.